However, as there are several pathophysiological links that could explain SNS drive reduction with the use of SGLT2 inhibitors, future, more well-designed studies, are necessary in order to fully comprehend whether these agents could ultimately exhibit a benefit in HF-related autonomic dysfunction [131]. The gene discussed is SLC5A2; the disease is hydrops fetalis.